Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > BNN-Bloomberg Nasal Spray to Fight SARS-Cov-2 Coronovirus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(24)
•••
Comment by Enzolinion Mar 25, 2021 11:52pm
142 Views
Post# 32884184

RE:RE:RE:RE:BNN-Bloomberg Nasal Spray to Fight SARS-Cov-2 Coronovirus

RE:RE:RE:RE:BNN-Bloomberg Nasal Spray to Fight SARS-Cov-2 Coronovirus Do any of you realize how many millions of dollars were reaised for there gvhd program?? Go back, and go back and see how long I've been a kalytera shareholder!! They don't have anything  and Robert will make you believe ( if you call him ) that they have great news coming like I believe for over 3 years now! Guys do what ever you want please don't listen to me do your own DD! But one thing I promise all of you is that the stock price will never hit one dollar, or 50 cents even better 10 cents! I've walked this stock down from over 50 cents so guys don't tell me anything about this stock, I've seen and heard it all from Robert. I had nothing to lose but you guys do! Do me all a favour and please read back all the news releases and go way back. If your not a idiot you will see a lot of things that a common from there last breakthrough! I'm out and again to all you guys who think this thing has a chance well maybe in hel!
!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities